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Traditional Chinese medicine (TCM) syndrome, also called ZHENG, is the basis concept of TCM theory. It plays an important
role in TCM practice. There are excess and deﬁciency syndromes in TCM syndrome. They are the common syndromes in chronic
hepatitis B (CHB) patients. Here we aim to explore serum protein proﬁles and potential biomarkers for classiﬁcation of TCM
syndromes in CHB patients. 24 healthy controls and two cohorts of CHB patients of excess syndrome (n = 25) or deﬁciency
syndrome (n = 19) were involved in this study. Protein proﬁles were obtained by surface-enhanced laser desorption ionization
time-ﬂight mass spectrometry (SELDI-TOF/MS) and multiple analyses were performed. Based on SELDI ProteinChip data,
healthycontrolsandCHBpatientsorexcessanddeﬁciencysyndromesinCHBpatientswereobviouslydiﬀerentiatedbyorthogonal
partial least square (OPLS) analysis. Two signiﬁcant serum proteins (m/z 4187 and m/z 5032) for classifying excess and deﬁciency
syndromes were found. Moreover, the area under the receiver operating characteristic (ROC) curve was 0.887 for classifying excess
and nonexcess syndrome, and 0.700 for classifying deﬁciency and nondeﬁciency syndrome, respectively. Therefore, the present
study provided the possibility of TCM syndrome classiﬁcation in CHB patients using a universally acceptable scientiﬁc approach.
1.Introduction
Traditional Chinese medicine (TCM) syndrome classiﬁca-
tion (also deﬁned as Zheng diﬀerentiation) and treatment is
the basis concept of TCM theory. TCM syndrome, a proﬁle
of symptoms and signs as a series of clinical phenotypes,
plays an important role in understanding the human home-
ostasis and guiding the applications of Chinese herbs and
acupuncture. Heat, cold, excess, and deﬁciency are the four
basicsyndromesofmaladjustmentnatureinTCM[1].Damp
heat stasis syndrome and liver and kidney Yin deﬁciency
syndrome, classiﬁed as excess syndrome and deﬁciency syn-
drome, respectively, are the common syndromes in chronic
hepatitis B (CHB) patients [2]. Excess syndrome refers to
the accumulation or stagnation of metabolic waste, body
ﬂuids, and blood, whereas deﬁciency syndrome means to
“overcatabolism” and “overconsumption”, the deﬁciency of
nutrients, and weakness [1].
So far, an experiential diagnosis approach has been
always used to classify excess syndrome and deﬁciency
syndrome in CHB patients. TCM practitioners with rich
experience in TCM diagnosis and treatment are often able
to improve the symptoms of CHB patients, which may be
considered to be untreatable by conventional medicine [3].
Lu et al. [4] mentioned that for coronary heart patients with
diﬀerent TCM syndromes, if herbal medicine was appropri-
ate to TCM syndrome, the eﬀective rate would increase. It
was suggested that syndrome classiﬁcation acts as a pivot in
the therapeutic process and directly aﬀects the therapeutic
result of a speciﬁc disease. Instead of experiential diagnosis,2 Evidence-Based Complementary and Alternative Medicine
therefore, it is necessary to standardize the diagnosis criteria
for classiﬁcation of excess and deﬁciency syndromes in
patientswithCHB by using auniversallyacceptablescientiﬁc
approach.
Proteomics, a rapidly evolving tool in systems biology
of analyzing protein expression in a comprehensive degree,
is widely applied for disease diagnosis and prognosis, such
as brain injury [5], appendicitis [6], liver ﬁbrosis [7], and
esophageal cancer [8]. Surface-enhanced laser desorption
ionization time-ﬂight mass spectrometry (SELDI-TOF/MS),
a powerful tool for global analysis of protein expression,
provides an eﬃcient and sensitive method for biomarker
discovery. It can obtain the spectra composed of hundreds
of protein peaks, each characterized by its mass-to-charge
ratio (m/z) and each area represented by its amount [9].
Considering the features of measuring in a high-throughput
way and analyzing with a small amount of materials,
SELDI-TOF/MS has become an attractive tool for clinical
application. The technology has successfully led to the
discovery of new biomarkers for diagnosis and treatment
of various diseases, for example, accurate diagnosis of early
hepatocellular carcinoma [10] and laryngeal carcinoma [11],
and identiﬁcation of treatment eﬃcacy-related host factors
in chronic hepatitis C [12].
CHB is a kind of global infective disease induced by hep-
atitis virus B (HBV). It is estimated that about 400 million
people are suﬀering from HBV infection worldwide [13, 14].
And HBV leads to 500,000 to 1.2 million deaths every year
because of turning into liver cirrhosis and hepatocellular
carcinoma (HCC) [15]. With 120 million people infected
with HBV, China has the largest population in the world.
Andamongthem,about30millionpeoplearesuﬀeringfrom
CHB [3]. TCM is widely used in the treatment of CHB and
was found to be eﬀective in China [16–18], and conventional
medicine hardly heals CHB patients completely, so more and
more people therefore turn to get help from TCM. In the
present study, we aim to use SELDI-TOF/MS analysis and
relateddataprocessingmethodstoﬁndtheproteinproﬁlesof
excess and deﬁciency syndromes and the promising protein
biomarkers to classify these TCM syndromes in patients with
CHB.
2.MaterialandMethods
2.1. Study Population. The study has been approved by Shu-
guang Hospital, the aﬃliated hospital of Shanghai University
of TCM. Serum samples were collected from November 2009
to July 2010. The experiment involved 24 healthy controls
and two cohorts of CHB patients of excess syndrome (n =
25) or deﬁciency syndrome (n = 19). The demographic
and clinicopathological data about the participants were
showed in Table 1.T h ed i ﬀerences of gender and age have
no statistical signiﬁcance among three groups (P>0.05).
The selected 44 patients with CHB must be in accordance
with the following criteria: (1) all patients were diagnosed
according to both CHB and TCM syndromes and conﬁrmed
by chief physicians; (2) the diagnosis of CHB was based on
the guideline deﬁned by the Chinese Society of Hepatology
and Chinese Society of Infectious Diseases in 2005 [19];
(3) the TCM syndrome diﬀerentiation was referred to the
viral hepatitis diagnostic standard described by the Internal
Medicine Hepatopathy Committee of Chinese Traditional
Medicine Association in December, 1991 [20]. An informed
consent was signed by each of the participants, and the
study protocol conformed to the ethical guidelines of the
Declaration of Helsinki (1964).
The fasting blood samples were collected from two
experimental groups of patients with CHB and healthy
controls in the morning and allowed to stand for 30min at
room temperature and then centrifuged at 1,5000rpm for
10min. All the serum samples were stored at −80◦C until
further analysis.
2.2. Protein Proﬁling by SELDI-TOF/MS. CM10 (Cipher-
gen Biosystems, Fremont, CA, USA) was used to further
serum diﬀerential protein spectrum analysis. First, 5μLo f
the cleared serum was mixed with 10μLo fU 9s o l u t i o n
containing 9mol/L urea, 2% CHAPS, 50mmol/L Tris/HCl,
and 1% DTT (pH 9.0; Sigma, USA). Subsequently, the
previous sample was diluted with 185μL CM10-binding
buﬀer (50mmol/L sodium acetate, pH 4.0; Sigma, USA)
to give a ﬁnal dilution of 40-fold. In addition, the array
spots should be preactivated twice with 200μL of binding
buﬀer for 5min. And then, 100μL of diluted serum samples
was loaded on each array spot and incubated with shaking
for 1h at 4◦C. Two washes with binding buﬀer and one
quick rinse with HPLC grade water were continued to
remove nonselectively bound proteins. After air-drying,
0.5μL of freshly prepared sinapinic acid solution in 0.5%
triﬂuoroacetic acid and 50% acetonitrile was added on each
spot for twice. The chips were ready for MS detection when
dried.
Mass accuracy was calibrated externally by using the all-
in-one peptide molecular mass standard. After calibration
passed, the chips were scanned by SELDI-TOF/MS in a PBS-
Iic ProteinChip reader (Ciphergen Biosystems) to measure
the masses and intensities of the protein peaks. According
to experience, many parameters were optimized for getting
more protein peaks and separating these peaks better. At
last, the reader was set up as follows: laser intensity, 100;
laser sensitivity, 8; optimized mass range, 2,000–15,000Da;
focus mass, 8,500Da; high mass, 50,000Da; and data
acquisition parameters, 25 delta to 5 transients per to 10
ending position to 75. Data were processed automatically
using the Ciphergen Protein-Chip Software (version 3.1.1,
Ciphergen Biosystems). Spectra were normalized, calibrated,
and aligned.
2.3. Data Processing. Protein spectra were automatically
generated after all raw data were collected. The proﬁling
spectra of serum samples were ﬁrst normalized using total
ion current by Ciphergen ProteinChip Software 3.1.1. Peak
selection was carried out by the Biomarker Wizard program.
Protein peaks were selected based on a ﬁrst pass of signal-to-
noise ratio of 5. This process was completed with a second
pass of signal-to-noise ratio of 2, and peak selection atEvidence-Based Complementary and Alternative Medicine 3
Table 1: Clinical parameters and TCM syndromes in CHB patients and controls.
Clinical parameters Excess syndrome (n = 25) Deﬁciency syndrome (n = 19) Healthy control (n = 24)
gender (M/F) 21/41 4 /51 5 /9
age (year) 38.0 ±13.43 8 .1 ±11.13 6 .4 ±11.6
BMI (Kg/m2)2 3 .2 ±3.02 2 .1 ±2.72 1 .3 ±2.1
ALT (U/L) 91.8 ±116.85 7 .4 ±41.72 0 .7 ±8.7
AST (U/L) 59.8 ±54.45 0 .5 ±29.11 9 .9 ±5.5
GGT (U/L) 47.8 ±47.75 6 .8 ±72.02 1 .5 ±9.8
ALP (U/L) 84.2 ±21.49 0 .2 ±34.75 8 .0 ±20.2
ALB (g/L) 45.2 ±4.14 4 .2 ±3.54 3 .9 ±5.7
TG (mmol/L) 1.1 ±0.41 .4 ±0.70 .8 ±0.3
BA (μmol/L) 10.3 ±15.91 3 .0 ±18.28 .0 ±1.8
TBIL (μmol/L) 19.8 ±8.31 8 .9 ±5.21 5 .0 ±3.8
PT (s) 13.4 ±2.01 3 .2 ±1.81 2 .7 ±0.8
HbsAg (+/−)2 5 /01 9 /00 /24
HBV DNA (+/−)1 9 /61 1 /80 /24
0.3% of the mass window, and the estimated peaks were
added.Afterthepreliminaryanalysisofproteinspectra,these
selected protein peaks were exported to other commercially
available software for further analysis.
The statistical analysis was performed by SPSS software
(version 15.0, Chicago, IL, USA). Values are expressed as
the mean ± SD. The baseline characteristics were compared
using appropriate method. For continuous variables, one-
way factorial analysis was used, or the Wilcoxon rank-sum
test was used because of the skewed distributions. And for
categorical variables, x2 test was used. Multivariate analysis
was carried out to determine the independent variables
associated with diﬀerentiation of syndromes. Two-sided P
value < 0.05 for one-way factorial analysis or adjusted P
value < 0.0167 for Wilcoxon rank-sum test was considered
statistically signiﬁcant. SELDI-TOF/MS-measured variables
showing statistical signiﬁcance on univariate analysis were
subjected to binary logistic regression to determine signiﬁ-
cant independent factors. After the regression, the values of
the prediction probability were applied to the classiﬁcation
of the samples. Then receiver operating characteristic curve
(ROC) was made by using the SPSS software.
The preprocessed data obtained by Ciphergen Pro-
teinChip Software were also exported and analyzed by
principle component analysis (PCA) and orthogonal partial
least squares (OPLSs) using the SIMCA-P software (version
11.5, Umetrics AB, Umea, Sweden).
3. Results
3.1. Clinical Characteristics of Study Population. Clinical
characteristics and TCM syndromes in CHB patients and
healthy controls are shown in Table 1. Data including body
mass index (BMI), alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), γ-Glutamyltransferase (GGT),
alkaline phosphatase (ALP), albumin (ALB), triglyceride
(TG), bile acid (BA), total bilirubin (TBIL), prothrombin
time (PT), Hepatitis B surface antigen (HbsAg), and HBV
DNA were expressed as the mean ± SD. According to
the statistical analysis, no clinical factors were signiﬁcantly
diﬀerent between excess syndrome and deﬁciency syndrome,
indicating that the two TCM syndromes could not been
classiﬁed by the general clinical parameters of CHB.
3.2. Serum Protein Proﬁling by SELDI-TOF/MS. Using the
SELDI ProteinChip system, we analyzed the serum protein
proﬁling from 24 healthy controls, 25 excess syndrome
patients with CHB, and 19 deﬁciency syndrome patients
with CHB. Peaks were detected automatically after baseline
subtraction. 184 protein peaks were detected and these peaks
were overlapping among 3 groups. Figure 1(a) displays the
representative protein proﬁling obtained by SELDI-TOF/MS
analysis showing the protein peaks of healthy controls
and CHB patients of two diﬀerent TCM syndromes. As
shown, the SELDI technology was eﬀective in separating low
molecular weight proteins and polypeptides between m/z
2,000 and m/z 15,000.
3.3. Classiﬁcation of TCM Syndromes by Pattern Recognition
Analysis. To explore whether the serum protein proﬁles
could help to classify excess syndrome and deﬁciency
syndrome in CHB patients, pattern recognition analysis
was carried out to analyze the data generated by SELDI-
TOF/MS. Principle component analysis (PCA) was ﬁrst used
as an unsupervised statistical method to study the protein
diﬀerences among the three groups. The result showed
that there was not a trend of separation between control
group and CHB group or excess syndrome and deﬁciency
syndrome groups (Figure 2(a)). Then a supervised statistical
method, that is orthogonal partial least squares (OPLSs)
analysis, was performed as mentioned before. As OPLS
score plots were displayed, a tendency of separation was
observed among the three groups (Figure 2(b)), and an
obvious separation exists between excess syndrome group
and deﬁciency syndrome group (Figure 2(c)), indicating that
the whole protein expression was diﬀerent not only between4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Representative protein proﬁles of serum samples of healthy controls and patients with CHB of excess symptom and deﬁciency
syndrome. Protein peak spectrum of serum was analyzed by the SELDI-TOF/MS system, and representative protein peaks within m/z 0–
1,5000 of three groups are shown (a). Statistically signiﬁcantly diﬀerent peaks between excess syndrome and deﬁciency syndrome are shown
in the enlarged view, m/z 3168 on the left and m/z 4187 on the right (b).
healthy controls and CHB patients but also between excess
and deﬁciency syndromes in CHB patients.
Ontheotherhand,toinvestigatewhetherclinicalparam-
etershadinﬂuenceonclassiﬁcation,thePCAmodelcompar-
ing three groups was constructed using clinicopathological
data alone. But the result was not satisfying and the groups
could not be diﬀerentiated from each other (not shown).
And then the OPLS model was carried out. As shown in
Figure 2(d), only the control group could be separated from
the two others, whereas the TCM syndrome groups could
not be separated from each other. It was suggested that the
generalclinicaldataweregoodatclassifyinghealthandHBC,
while the data from SELDI-TOF/MS could be used for TCM
syndrome classiﬁcation.
3.4. Serum Protein Potential Biomarkers of TCM Syndromes.
Among a total of 184 protein peaks detected, 4 signiﬁcantly
diﬀerent peaks were observed between excess and deﬁciency
syndromes according to Wilcoxon rank-sum test. Three
of four protein peaks were in lower abundance in excess
syndrome group (Figures 3(a), 3(b),a n d3(c)), and the
remaining one was in higher abundance (Figure 3(d)). These
statistically signiﬁcant diﬀerences can be displayed clearly
in the box-plots. Also, an enlarged view of m/z 3168 and
m/z 4187 is shown in Figure 1(b). So they may be potential
biomarkers for classifying excess syndrome and deﬁciency
syndrome with CHB.
3.5. Logistic Regression Analysis. To identify the variables
independently associated with TCM syndromes in CHB
patients and to compare the value of SELDI data and clinical
parametersinclassifyingTCMsyndromes,logisticregression
analysiswasperformedincludingSELDI-TOF/MS-measured
four signiﬁcantly diﬀerent variables displayed in Figure 3
and some clinical parameters listed in Table 1. As shown
in Table 2, two protein peaks were independent factors
that were associated with TCM syndromes and no clinical
parameters were selected. Just as mentioned in Section 3.3,i t
wasprovenagainthatthegeneralclinicaldatawereonlygood
at classifying health and HBC, while the method of SELDI-
TOF/MS could be used for TCM syndrome classiﬁcation.
Then peak m/z 4187 and peak m/z 5032 were applied to
the classiﬁcation of diﬀerent TCM syndrome. And 88% of
excess syndrome patients and 73.7% of deﬁciency syndrome
patients were correctly discriminated (cutoﬀ value: 0.5,
Figure 4).
3.6. Sensitivity and Speciﬁcity of Serum Protein Markers for
TCM Syndrome Classiﬁcation. To determine the sensitivity
and speciﬁcity of serum protein potential biomarkers and
theusefulnessofproteinpeakquantiﬁcationsasclassiﬁcation
of diﬀerent TCM syndromes, ROC analysis was conducted.
To increase the performance of the classiﬁcation, the most
eﬃcient peak combination was determined using regression
analysis. Control group and deﬁciency syndrome group
were put together and deﬁned as the nonexcess syndrome
group, so ROC analysis was carried out for discriminating
excess syndrome with nonexcess syndrome. The area under
the ROC curve for the combination of m/z 4187 and m/z
5032 was 0.887 (Figure 5(a)). In the same way, ControlEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: PCA score plot and OPLS score plots of 25 CHB patients of excess syndrome (), 19 CHB patients of deﬁciency syndrome (),
and 24 healthy controls (∗) based on the serum protein proﬁling detected from SELDI-TOF/MS or the clinicopathological data of each
individuals. (a) PCA score plot among the control group and CHB groups of excess syndrome and deﬁciency syndrome; OPLS score plots
(b) among the control group and CHB groups of excess syndrome and deﬁciency syndrome and (c) between excess syndrome group and
deﬁciency syndrome group. (a)–(c) Models of score plots were constructed by the data from SELDI-TOF/MS. (d) Another OPLS score plot
among the three groups using clinical parameters.
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Figure 3: Box-plots for protein peak comparison between TCM syndrome groups. Proteins m/z 1216 (a), m/z 3168 (b), and m/z 4187
(c) were in lower abundance in excess syndrome group than those in deﬁciency syndrome one, while protein m/z 5032 (d) was in higher
abundance.6 Evidence-Based Complementary and Alternative Medicine
Table 2: Logistic regression analysis for TCM syndrome classiﬁca-
tion in CHB patients.
Factors Odds ratio 95% CI P value
m/z 4187 1.349 1.100–1.655 0.004
m/z 5032 0.054 0.005–0.597 0.017
m/z 1216 — — 0.894
m/z 3168 — — 0.097
BMI (Kg/m2) — — 0.301
ALT (U/L) — — 0.544
AST (U/L) — — 0.452
GGT (U/L) — — 0.074
ALP (U/L) — — 0.779
ALB (g/L) — — 0.093
TG (mmol/L) — — 0.262
BA (μmol/L) — — 0.206
TBIL (μmol/L) — — 0.901
PT (s) — — 0.150
group and excess syndrome group were put together and
deﬁnedasthenondeﬁciencysyndromegroup,andthenROC
analysiswasperformedtodiscriminateexcesssyndromewith
nonexcess syndrome. The area under the ROC curve was
0.700 (Figure 5(b)). It was suggested that the quantiﬁcation
of these variables by SELDI-TOF/MS was useful to classify
excess and deﬁciency syndromes (Figure 5).
4. Discussion
TCM practitioners classify biomedical maladjustments into
diﬀerent syndromes, and each syndrome has its own suitable
treatment protocol. Also, considering that the mechanism
of disease might not be identical in diﬀerent people,
that is to say, one disease could display several diﬀerent
syndromes, so the same disease may be treated by diﬀerent
therapeutic approaches. The syndrome classiﬁcation-based
individualized therapy is commonly applied in the TCM
p r a c t i c e .S ow eh a v es u ﬃcient reasons to believe that the
therapeutic eﬀect will be inﬂuenced if excess syndrome and
deﬁciency syndrome of CHB patients were not classiﬁed
correctly. Therefore, much attention should be paid to
the accuracy and the standard of syndrome classiﬁcation.
However, people often argue that the diagnostic approach of
TCMpractitionersdoesnotmeetrequirementsofobjectivity
and reproducibility. And TCM diagnosis studies have proved
that there exists considerable variability across diﬀerent
practitioners, even when the same patient was diagnosed
[21, 22]. So it is essential to ﬁnd a kind of scientiﬁc and
persuasive approach for the application of TCM syndrome
classiﬁcation.
Proteomicsisplayinganimportantroleinimprovingour
understanding of biologic systems by observing the diﬀerent
interactionsamonghundredsofproteinssimultaneouslyand
aims at studying proteins of human body in the level of
integrity. It happens to be in accordance with the viewpoint
of TCM, which has always been emphasized on the integrity
of human body and the close relationship between human
and its environment [3]. In addition, the characteristics of
proteomicsmakeitpossibletointegratevariousproteins[23]
and easy to study TCM syndrome classiﬁcation. Comparing
with the traditional method that syndromes are classiﬁed
into groups based on TCM theory and clinical experi-
ences, they can be clustered into speciﬁc groups using the
approaches of proteomics and bioinformatics. Matsumoto
et al. found several proteins for the diagnosis of “Oketsu”, a
pathophysiologic concept of Japanese traditional medicine,
and diﬀerentiated “Oketsu” with “non-Oketsu” successfully
[24]. Obviously, it is more scientiﬁc and more persuasive. As
described in this paper, a proteomics approach was applied,
which aimed to provide a kind of accurate and reliable
method for TCM syndrome classiﬁcation.
In this study, we used the ProteinChip system to analyze
and compare the serum protein proﬁles of excess and
deﬁciency syndromes in CHB patients to deﬁne the new
potential protein biomarkers for syndrome classiﬁcation.
According to pattern recognition analysis, excess and deﬁ-
ciencysyndromeswereobservedtobeclusteredintodiﬀerent
groups. And four protein peaks were found statistically
signiﬁcant when both groups were compared. On the other
hand, syndrome groups could not be classiﬁed using general
clinical data, and no clinical data were found signiﬁcantly
diﬀerent between TCM syndrome groups. Among those four
possible protein markers, three (m/z 1216, m/z 3168, and
m/z 4187) were overexpressed in the deﬁciency syndrome
group and one (m/z 5032) was increased in the group of
excess syndrome. Multivariate regression analysis performed
by using four signiﬁcantly diﬀerent protein peaks from
SELDI-TOF/MS data and laboratorial serum markers from
clinical data showed the usefulness of two protein peaks
(peak m/z 4187 and peak m/z 5032) for excess and deﬁciency
syndromes classiﬁcation. To observe the sensitivity and
speciﬁcity of the two proteins, ROC curve analysis was con-
ducted to diﬀerentiating excess with nonexcess syndromes
and deﬁciency with nondeﬁciency syndromes. The area
under the ROC curve was 0.887 and 0.700, respectively,
suggesting that they could be applied for the classiﬁcation of
TCM syndromes in CHB patients.
Since one disease could display multiple syndromes in
TCMtheory,thisstudyfocusedonseveralsubgroupsofCHB
patients. It would make protein proﬁles of diﬀerent patients
keep in the same level of a speciﬁc disease and eliminate the
interferenceofdiseasesforlooking forbiomarkersclassifying
diﬀerent syndromes.
Also, comparing healthy controls with CHB patients of
excess syndrome or deﬁciency syndrome, signiﬁcant vari-
ables were supposed to represent the potential biomarkers
about CHB disease and excess syndrome or deﬁciency syn-
drome, and the common variables were supposed to rep-
resent the potential biomarkers between CHB and healthy
group. So in order to ﬁnd out potential biomarkers for
classifyingTCMsyndromes,thoseaboutCHBdiseaseshould
beeliminatedfromthesigniﬁcantvariablescomparingexcess
syndrome with deﬁciency syndrome. Therefore, 27 signif-
icantly diﬀerent serum proteins between healthy controls
and excess syndrome might be the potential biomarkers
for CHB disease and excess syndrome. In the same way,Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Diagnostic potential of the two marker proteins (m/z 4187 and m/z 5032) using binary logistic regression method with the data
from diﬀerent TCM syndromes in CHB patients. 88% of excess syndrome patients and 73.7% of deﬁciency syndrome patients were correctly
discriminated (cutoﬀ value: 0.5).
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Figure 5: ROC curve for classiﬁcation of two diﬀerent TCM syndromes in CHB patients. It was generated combining the peak values of m/z
4187 and m/z 5032. (a) ROC curve for classiﬁcation of excess syndrome and non-excess syndrome. AUC (area under the curve) = 0.887. (b)
ROC curve for classiﬁcation of deﬁciency syndrome and nondeﬁciency syndrome. AUC = 0.700.
28 signiﬁcantly diﬀerent ones between healthy controls and
deﬁciency syndrome might be the potential biomarkers for
CHB disease and deﬁciency syndrome (Table 3). And 9
c ommonpr ot eins(mark edinboldinT able3)weresupposed
to represent the potential biomarkers between CHB and
healthy group, which should be eliminated from those
signiﬁcantly diﬀerent proteins between excess syndrome and
deﬁciency syndrome. However, these 9 proteins were totally
diﬀerent with those 4 ones found when comparing between
TCM syndrome groups. So it was demonstrated that the
interference of diseases to biomarkers had been eliminated.
Most importantly, this study is the ﬁrst time to classify
TCM syndromes in CHB patients by an objective and scien-
tiﬁc approach instead of a subjective and experiential one.
Our work found the characteristic markers in biochemistry
associated with speciﬁc TCM syndromes and it will facilitate
the development of syndrome classiﬁcation. Also, it provides
animportantdirectionfortheunderstandingandacceptance
of TCM theory all around the world. Furthermore, the
incorporation of SELDI-based ProteinChip technology into
TCM syndrome classiﬁcation will lead to a new era in the
development of TCM to improve treatment eﬃcacy. Our8 Evidence-Based Complementary and Alternative Medicine
Table 3: Signiﬁcantly diﬀerent peaks between healthy controls and excess or deﬁciency syndromes.a
m/z Healthy controls Excess or deﬁciency syndrome Changeb P value
Healthy control versus excess syndrome
1174 0.20 ±0.49 0.69 ±1.17 ↑ 0.011
2037 1.71 ±0.71 3.10 ±2.24 ↑ 0.010
2269 0.86 ±0.38 1.62 ±1.25 ↑ 0.011
2592 0.49 ±0.27 −0.04 ±0.34 ↓ 0.002
3203 2.38 ±1.22 0.13 ±0.42 ↓ 0.001
3408 1.71 ±0.80 0.21 ±0.51 ↓ 0.000
4104 32.07 ±13.66 11.11 ±6.43 ↓ < 0.001
4187 11.66 ±4.61 4.08 ±3.33 ↓ 0.004
429 7.98 ±2.88 3.64 ±2.53 ↓ 0.001
4311 4.79 ±1.46 1.97 ±2.70 ↓ < 0.001
5032 −0.05 ±0.33 0.48 ±0.56 ↑ < 0.001
5497 1.75 ±0.79 0.37 ±0.39 ↓ < 0.001
5650 18.09 ±6.50 9.10 ±5.46 ↓ 0.001
7027 2.10 ±0.75 3.33 ±1.97 ↑ 0.007
7587 1.19 ±0.45 2.07 ±1.43 ↑ 0.015
11732 0.52 ±0.26 1.04 ±0.68 ↑ 0.001
14070 0.55 ±0.23 0.98 ±0.65 ↑ 0.008
15167 1.95 ±1.45 4.50 ±4.42 ↑ 0.002
15354 0.49 ±0.43 1.22 ±1.24 ↑ 0.002
22862 1.09 ±0.63 2.31 ±1.47 ↑ < 0.001
23481 2.25 ±1.36 4.78 ±2.65 ↑ < 0.001
28118 1.72 ±0.65 2.31 ±1.02 ↑ 0.013
33516 0.13 ±0.28 0.37 ±0.68 ↑ 0.004
38571 0.04 ±0.02 0.08 ±0.08 ↑ 0.005
38814 0.04 ±0.02 0.08 ±0.08 ↑ 0.007
46804 0.03 ±0.03 0.09 ±0.08 ↑ < 0.001
47818 0.02 ±0.01 0.04 ±0.04 ↑ 0.015
Healthy control versus deﬁciency syndrome
1074 0.49 ±0.48 0.13 ±0.37 ↓ 0.013
1210 1.89 ±1.42 2.64 ±1.02 ↑ 0.006
1216 6.03 ±3.50 9.26 ±3.39 ↑ 0.002
1261 21.14 ±9.18 29.16 ±10.80 ↑ 0.014
1440 0.79 ±1.03 1.36 ±0.95 ↑ 0.004
2003 1.97 ±1.04 4.32 ±2.74 ↑ <0.001
2018 6.92 ±3.50 13.81 ±7.86 ↑ 0.001
2037 1.71 ±0.81 3.62 ±2.51 ↑ 0.001
2269 0.86 ±0.47 1.93 ±1.08 ↑ < 0.001
3331 3.78 ±2.69 6.43 ±3.33 ↑ 0.006
4104 32.07 ±18.72 16.01 ±11.01 ↓ 0.005
5260 0.80 ±1.44 1.96 ±1.79 ↑ 0.004
5346 9.05 ±13.75 21.53 ±15.00 ↑ 0.007
5497 1.75 ±1.37 0.49 ±0.50 ↓ 0.001
5558 0.97 ±1.40 1.85 ±1.32 ↑ 0.007
5650 18.09 ±10.43 10.39 ±7.67 ↓ 0.015
5919 23.56 ±16.61 40.84 ±22.76 ↑ 0.014
5947 2.98 ±3.47 6.79 ±5.24 ↑ 0.010
6128 4.83 ±5.95 9.72 ±6.92 ↑ 0.003
8176 2.82 ±2.70 4.31 ±2.73 ↑ 0.010
9723 0.37 ±0.31 0.83 ±0.51 ↑ 0.002
10292 1.17 ±0.98 2.40 ±1.22 ↑ 0.001Evidence-Based Complementary and Alternative Medicine 9
Table 3: Continued.
m/z Healthy controls Excess or deﬁciency syndrome Changeb P value
11732 0.52 ±0.36 0.90 ±0.42 ↑ 0.004
15009 0.07 ±0.09 0.60 ±1.86 ↑ 0.002
22572 0.30 ±0.23 0.93 ±1.18 ↑ <0.001
22862 1.09 ±0.61 2.39 ±1.35 ↑ < 0.001
23481 2.25 ±1.53 4.74 ±2.62 ↑ < 0.001
46804 0.03 ±0.02 0.08 ±0.06 ↑ < 0.001
aProteinpeaksmarkedinboldwerethecommonbiomarkersforCHBdisease. b “↑”and“ ↓”representtheproteinwasup-anddownregulatedinCHBpatients
compared with the control, respectively.
researched results also suggest that TCM syndromes really
have their own biological fundament.
5. Conclusion
The SELDI-based proteomics found some promising protein
proﬁles and potential biomarkers to classify excess and
deﬁciency syndromes in CHB patients, and it provided
an evidence for objective TCM syndrome classiﬁcation.
However, there also exist some limitations in the study,
such as the small amount of study population and lack
of identiﬁcation of candidate biomarkers, which would be
researched in future study.
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